Helsinn to Present at UBS Global Healthcare Conference in New York
Tuesday 23rd May 2017, at 08:30am EDT

Lugano, Switzerland, May 19, 2017 - Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, announces that William Mann, Helsinn Therapeutics (U.S.), Inc, President & CEO, will present at the UBS Global Healthcare Conference on Tuesday 23rd May at 08:30am EDT at the Grand Hyatt, New York City, USA.

Mr. Mann will give a business overview of the Helsinn Group with a special focus on Helsinn's U.S. operations.

About the Helsinn Group

Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland and the U.S., a representative office in China as well as a product presence in approximately 190 countries globally.

Please visit www.helsinn.com

For more information please contact:

Helsinn Group

Paola Bonvicini

Group Head of Communication

Lugano, Switzerland

Tel: +41 (0) 91 985 21 21



You May Also Like

HTG Molecular Diagnostics Announces VERI/O Laboratory Service

TUCSON, Ariz., June 23, 2016 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a ...

ContraFect to Present at the 2nd Annual Superdrugs and Superbugs USA Conference

YONKERS, N.Y., Nov. 10, 2017 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company ...

Inovio HIV Vaccine Elicits Nearly 100% Immune Response Rates in a Clinical Study

PLYMOUTH MEETING, Pa., May 24, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today ...